Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Barratt-Redrow merger to complete this week as housebuilders engage with CMA

(Sharecast News) - Barratt Developments and Redrow have reported that their impending £2.5bn merger should complete later this week despite local competition concerns raised by regulators. Both parties are now engaging with the Competition and Markets Authority following the conclusion of its first review earlier this month, which raised concerns about the supply of new build private residential housing in one of the more than 400 local areas where the two companies overlap.

Barratt has now waived the CMA condition to the merger, which "removes uncertainty for the employees, supply chain and wider stakeholder groups of both businesses".

Barratt and Redrow said in a statement on Monday that they are continuing to engage with the CMA with the objective of agreeing "suitable undertakings" which would address the CMA's concerns "and avoid the need for a reference to a full Phase 2 investigation".

The CMA will likely enforce a so-called initial enforcement order on both parties, preventing them from integrating to the two businesses until they agree on conditions to settle the competition concerns.

"Barratt confirms that it remains its intention to begin full integration as soon as practicable and permissible. Barratt also confirms that its intention remains to substantially complete the implementation of an integration plan within 18 months of completion, with synergies expected to be realised fully within three years following completion," the companies said in a statement.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.